Ignite Creation Date:
2025-12-24 @ 5:08 PM
Ignite Modification Date:
2025-12-27 @ 9:55 PM
Study NCT ID:
NCT01268150
Status:
COMPLETED
Last Update Posted:
2023-06-22
First Post:
2010-12-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Sponsor:
Eisai Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-02
Start Date Type:
None
Primary Completion Date:
2012-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-08
Completion Date Type:
ACTUAL
First Submit Date:
2010-12-28
First Submit QC Date:
None
Study First Post Date:
2010-12-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-05-11
Results First Submit QC Date:
None
Results First Post Date:
2016-08-09
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-16
Last Update Post Date:
2023-06-22
Last Update Post Date Type:
ACTUAL